tradingkey.logo
tradingkey.logo
Search

Metavia Advances Glp-1-Based Obesity Program With Irb Approval For Higher-Dose Phase 1 Studies Of Da-1726, A Glp-1 And Glucagon Dual Agonist Demonstrating Best-In-Class Potential For Weight Loss And Glucose Control

ReutersMar 18, 2026 12:04 PM

- MetaVia Inc MTVA.O:

  • METAVIA ADVANCES GLP-1-BASED OBESITY PROGRAM WITH IRB APPROVAL FOR HIGHER-DOSE PHASE 1 STUDIES OF DA-1726, A GLP-1 AND GLUCAGON DUAL AGONIST DEMONSTRATING BEST-IN-CLASS POTENTIAL FOR WEIGHT LOSS AND GLUCOSE CONTROL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI